語系:
繁體中文
English
說明(常見問題)
登入
回首頁
切換:
標籤
|
MARC模式
|
ISBD
Drug Discovery in Japan = Investigat...
~
SpringerLink (Online service)
Drug Discovery in Japan = Investigating the Sources of Innovation /
紀錄類型:
書目-語言資料,印刷品 : Monograph/item
正題名/作者:
Drug Discovery in Japan/ edited by Sadao Nagaoka.
其他題名:
Investigating the Sources of Innovation /
其他作者:
Nagaoka, Sadao.
面頁冊數:
XV, 333 p. 57 illus., 33 illus. in color.online resource. :
Contained By:
Springer Nature eBook
標題:
Economic policy. -
電子資源:
https://doi.org/10.1007/978-981-13-8906-1
ISBN:
9789811389061
Drug Discovery in Japan = Investigating the Sources of Innovation /
Drug Discovery in Japan
Investigating the Sources of Innovation /[electronic resource] :edited by Sadao Nagaoka. - 1st ed. 2019. - XV, 333 p. 57 illus., 33 illus. in color.online resource.
Foreword -- Acknowledgement -- Chapter 1: Introduction -- Chapter 2: Compactin -- Chapter 3: Pravastatin (Pravachol, Mevalotin) -- Chapter 4: Rosuvastatin(Crestor) -- Chapter 5: Leuprorelin (Leuplin, Lupron, Viadur) -- Chapter 6: Oflaxacin and levofloxacin (Tarivid/Cravit) -- Chapter 7: Tamsulosin (Harnal, Flomax, OMNIC) -- Chapter 8: Pranlukast (Onon) -- Chapter 9: Tacrolimus (Prograf) -- Chapter 10: Pioglitazone (Actos, Glustin) -- Chapter 11: Donepezil (Aricept) -- Chapter 12: Candesartan (Blopress, Atacand) -- Chapter 13: Tocilizumab (Actemra,Ro-actemra) -- Chapter 14: Nivolumab (Opdivo) -- Chapter 15: Sources of innovation of drug discovery in Japan and its implications.
This book analyzes the drug-discovery process in Japan, based on detailed case studies of 12 groups of 15 innovative drugs. It covers the first statin in the world up to the recent major breakthrough in cancer therapy, the recent immune checkpoint inhibitor, the scientific discovery for which a 2018 Nobel Prize in Physiology or Medicine was awarded to Prof. Tasuku Honjo, Kyoto University. The book shows the pervasive high uncertainty in drug discovery: frequent occurrences of unexpected difficulties, discontinuations, serendipities, and good luck, significantly because drug discovery starts when the underlying science is incomplete. Thus, there exist dynamic interactions between scientific progress and drug discovery. High uncertainty also makes the value of an entrepreneurial scientist high. Such scientists fill the knowledge gaps by absorbing external scientific progress and by relentless pursuit of possibilities through their own research, often including unauthorized research, to overcome crises. Further, high uncertainty and its resolution significantly characterize the evolution of competition in the drug industry. The patent system promotes innovation under high uncertainty not only by enhancing appropriability of R&D investment but also by facilitating the combination of knowledge and capabilities among different firms through disclosure. Understanding such a process significantly benefits the creation of innovation management and policy practices.
ISBN: 9789811389061
Standard No.: 10.1007/978-981-13-8906-1doiSubjects--Topical Terms:
555567
Economic policy.
LC Class. No.: JF20-2112
Dewey Class. No.: 338.926
Drug Discovery in Japan = Investigating the Sources of Innovation /
LDR
:03529nam a22003975i 4500
001
1004141
003
DE-He213
005
20200704221637.0
007
cr nn 008mamaa
008
210106s2019 si | s |||| 0|eng d
020
$a
9789811389061
$9
978-981-13-8906-1
024
7
$a
10.1007/978-981-13-8906-1
$2
doi
035
$a
978-981-13-8906-1
050
4
$a
JF20-2112
072
7
$a
KJMV6
$2
bicssc
072
7
$a
SCI000000
$2
bisacsh
072
7
$a
KJMV6
$2
thema
082
0 4
$a
338.926
$2
23
245
1 0
$a
Drug Discovery in Japan
$h
[electronic resource] :
$b
Investigating the Sources of Innovation /
$c
edited by Sadao Nagaoka.
250
$a
1st ed. 2019.
264
1
$a
Singapore :
$b
Springer Singapore :
$b
Imprint: Springer,
$c
2019.
300
$a
XV, 333 p. 57 illus., 33 illus. in color.
$b
online resource.
336
$a
text
$b
txt
$2
rdacontent
337
$a
computer
$b
c
$2
rdamedia
338
$a
online resource
$b
cr
$2
rdacarrier
347
$a
text file
$b
PDF
$2
rda
505
0
$a
Foreword -- Acknowledgement -- Chapter 1: Introduction -- Chapter 2: Compactin -- Chapter 3: Pravastatin (Pravachol, Mevalotin) -- Chapter 4: Rosuvastatin(Crestor) -- Chapter 5: Leuprorelin (Leuplin, Lupron, Viadur) -- Chapter 6: Oflaxacin and levofloxacin (Tarivid/Cravit) -- Chapter 7: Tamsulosin (Harnal, Flomax, OMNIC) -- Chapter 8: Pranlukast (Onon) -- Chapter 9: Tacrolimus (Prograf) -- Chapter 10: Pioglitazone (Actos, Glustin) -- Chapter 11: Donepezil (Aricept) -- Chapter 12: Candesartan (Blopress, Atacand) -- Chapter 13: Tocilizumab (Actemra,Ro-actemra) -- Chapter 14: Nivolumab (Opdivo) -- Chapter 15: Sources of innovation of drug discovery in Japan and its implications.
520
$a
This book analyzes the drug-discovery process in Japan, based on detailed case studies of 12 groups of 15 innovative drugs. It covers the first statin in the world up to the recent major breakthrough in cancer therapy, the recent immune checkpoint inhibitor, the scientific discovery for which a 2018 Nobel Prize in Physiology or Medicine was awarded to Prof. Tasuku Honjo, Kyoto University. The book shows the pervasive high uncertainty in drug discovery: frequent occurrences of unexpected difficulties, discontinuations, serendipities, and good luck, significantly because drug discovery starts when the underlying science is incomplete. Thus, there exist dynamic interactions between scientific progress and drug discovery. High uncertainty also makes the value of an entrepreneurial scientist high. Such scientists fill the knowledge gaps by absorbing external scientific progress and by relentless pursuit of possibilities through their own research, often including unauthorized research, to overcome crises. Further, high uncertainty and its resolution significantly characterize the evolution of competition in the drug industry. The patent system promotes innovation under high uncertainty not only by enhancing appropriability of R&D investment but also by facilitating the combination of knowledge and capabilities among different firms through disclosure. Understanding such a process significantly benefits the creation of innovation management and policy practices.
650
0
$a
Economic policy.
$3
555567
650
0
$a
Management.
$3
558618
650
0
$a
Industrial management.
$3
556510
650
0
$a
Japan—History.
$3
1256832
650
1 4
$a
R & D/Technology Policy.
$3
669186
650
2 4
$a
Innovation/Technology Management.
$3
786196
650
2 4
$a
History of Japan.
$3
1104955
700
1
$a
Nagaoka, Sadao.
$e
editor.
$4
edt
$4
http://id.loc.gov/vocabulary/relators/edt
$3
1297551
710
2
$a
SpringerLink (Online service)
$3
593884
773
0
$t
Springer Nature eBook
776
0 8
$i
Printed edition:
$z
9789811389054
776
0 8
$i
Printed edition:
$z
9789811389078
776
0 8
$i
Printed edition:
$z
9789811389085
856
4 0
$u
https://doi.org/10.1007/978-981-13-8906-1
912
$a
ZDB-2-ECF
912
$a
ZDB-2-SXEF
950
$a
Economics and Finance (SpringerNature-41170)
950
$a
Economics and Finance (R0) (SpringerNature-43720)
筆 0 讀者評論
多媒體
評論
新增評論
分享你的心得
Export
取書館別
處理中
...
變更密碼[密碼必須為2種組合(英文和數字)及長度為10碼以上]
登入